Please ensure Javascript is enabled for purposes of website accessibility

Stock Market News: Sotheby's, Array Get Winning Bids on a Big Deal Day

By Dan Caplinger - Jun 17, 2019 at 11:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street was in an optimistic mood on Monday morning.

The stock market began the new week on a positive note, as stocks generally rose on Monday morning. Investors seemed ready to look forward to key decisions from the Federal Reserve and other central banks across the globe, with many hoping for more accommodative monetary policy that could spur economic growth. As of 11:15 a.m. EDT, the Dow Jones Industrial Average (^DJI -0.82%) was up 56 points to 26,145. The S&P 500 (^GSPC -1.58%) climbed 7 points to 2,894, and the Nasdaq Composite (^IXIC -2.69%) was higher by 59 points to 7,856.

During the lull between earnings seasons, merger and acquisition activity captured the most attention on Wall Street to start the week. Sotheby's (BID) announced that it had received an offer to help it go private, while Array BioPharma (ARRY) attracted interest from Pfizer (PFE 0.17%).

The hammer drops on Sotheby's

Shares of Sotheby's soared 57% on Monday morning after the auction house announced that it had agreed to an acquisition bid. BidFair USA will purchase the auctioneer in a move that will lead to Sotheby's becoming a privately held company.

Person at podium pointing next to an artwork, with Sotheby's logo on back wall.

Image source: Sotheby's.

BidFair is controlled by Patrick Drahi, a billionaire investor and art collector who is best known for his founding of the cable television and media company Altice USA. Under the terms of the deal, BidFair will pay $57 per share in cash for Sotheby's, which will value the auctioneer at about $3.7 billion.

Both parties seem excited about the deal. Sotheby's CEO Tad Smith noted that the acquisition "will provide Sotheby's with the opportunity to accelerate the successful program of growth initiatives of the past several years in a more flexible private environment." As for Drahi, he seemed like he'd just won an auction, pointing out that "Sotheby's is one of the most elegant and aspirational brands in the world."

Sotheby's has gone through a lot in recent years, as fluctuations in the art and collectibles markets have presented some challenges to the company. Yet even with the big premium to its share price recently, Sotheby's will still leave some investors disappointed that they won't be able to participate more fully in a potential rebound for the auction house.

Array looks healthy

Meanwhile, shares of Array BioPharma also jumped higher, skyrocketing 56% as shareholders digested an acquisition bid of their own. Pharmaceutical giant Pfizer decided to make a big pitch for the cancer treatment specialist, offering $11.4 billion to buy out Array. Under the deal's terms, investors would receive $48 per share in cash for their Array stock.

Pfizer is excited about the positive impact it believes the acquisition could have. The move will make Pfizer's biopharmaceutical business stronger and allow it to grow faster, especially in the key oncology segment, where Pfizer has a significant presence. Array will also dramatically expand the drug giant's pipeline of cancer therapies, as well as add further research infrastructure to Pfizer's worldwide network of facilities.

In particular, the two companies highlighted Array's combination treatment Braftovi and Mektovi in treating melanoma. With phase 3 trials ongoing to try to expand the indication for the combination to include metastatic colorectal cancer, many analysts see a lot of growth potential for the treatment.

For Pfizer, the acquisition will use up available cash and lead the company to raise debt, and some of those who pay attention to debt levels raised questions about whether Pfizer's bond rating would stay unchanged following the deal. Even with those concerns, though, Pfizer's stock was down just a fraction of a percent, and that suggests confidence in the buyout going forward.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Array Technologies, Inc. Stock Quote
Array Technologies, Inc.
ARRY
Sotheby's Stock Quote
Sotheby's
BID
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$31,618.16 (-0.82%) $-445.45
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$3,910.93 (-1.58%) $-62.82
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.97 (0.17%) $0.09
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$11,225.07 (-2.69%) $-380.97

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.